Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1973 3
1975 2
1976 2
1983 2
1985 3
1986 1
1987 1
1990 1
1992 2
1993 1
1994 4
1995 6
1996 3
1997 4
1998 5
1999 9
2000 17
2001 19
2002 35
2003 21
2004 39
2005 37
2006 47
2007 45
2008 40
2009 30
2010 36
2011 60
2012 61
2013 64
2014 62
2015 68
2016 51
2017 47
2018 68
2019 49
2020 30
Text availability
Article attribute
Article type
Publication date

Search Results

894 results
Results by year
Filters applied: . Clear all
Page 1
NY-ESO-1: a promising cancer testis antigen for sarcoma immunotherapy and diagnosis.
Smith SM, Iwenofu OH. Smith SM, et al. Chin Clin Oncol. 2018 Aug;7(4):44. doi: 10.21037/cco.2018.08.11. Chin Clin Oncol. 2018. PMID: 30173534 Free article. Review.
Cancer testis antigens (CTAs) are a family of proteins in which aberrant gene-activation and subsequent high level mRNA expression, are restricted to testicular germ cells and are seen in certain malignancies. Importantly, the restriction of this class
Cancer testis antigens (CTAs) are a family of proteins in which aberrant gene-activation and subsequent high level mRNA
NY-ESO-1 Based Immunotherapy of Cancer: Current Perspectives.
Thomas R, Al-Khadairi G, Roelands J, Hendrickx W, Dermime S, Bedognetti D, Decock J. Thomas R, et al. Front Immunol. 2018 May 1;9:947. doi: 10.3389/fimmu.2018.00947. eCollection 2018. Front Immunol. 2018. PMID: 29770138 Free PMC article. Review.
NY-ESO-1 or New York esophageal squamous cell carcinoma 1 is a well-known cancer-testis antigen (CTAs) with re-expression in numerous cancer types. ...Cancer treatment has been revolutionized over the last few decades with immunotherapy e …
NY-ESO-1 or New York esophageal squamous cell carcinoma 1 is a well-known cancer-testis antigen (CTAs) with re-expressi …
Cancer/Testis Antigens: Expression, Regulation, Tumor Invasion, and Use in Immunotherapy of Cancers.
Salmaninejad A, Zamani MR, Pourvahedi M, Golchehre Z, Hosseini Bereshneh A, Rezaei N. Salmaninejad A, et al. Immunol Invest. 2016 Oct;45(7):619-40. doi: 10.1080/08820139.2016.1197241. Epub 2016 Sep 7. Immunol Invest. 2016. PMID: 27603913 Review.
Cancer/testis antigens (CTAs) are named based on their expression pattern that is restricted in a number of normal and abnormal tissues. ...ABBREVIATIONS: AIRE: autoimmune regulator; cAMP: cyclic adenosine 3',5'-cyclic monophosphate; CEA: carcinoembryonic
Cancer/testis antigens (CTAs) are named based on their expression pattern that is restricted in a number of normal and
Combining Epigenetic and Immunotherapy to Combat Cancer.
Chiappinelli KB, Zahnow CA, Ahuja N, Baylin SB. Chiappinelli KB, et al. Cancer Res. 2016 Apr 1;76(7):1683-9. doi: 10.1158/0008-5472.CAN-15-2125. Epub 2016 Mar 17. Cancer Res. 2016. PMID: 26988985 Free PMC article. Review.
However, with the exception of melanoma, most patients do not respond to immunotherapy alone. A growing body of work has shown that epigenetic drugs, specifically DNA methyltransferase inhibitors, can upregulate immune signaling in epithelial cancer cells through de …
However, with the exception of melanoma, most patients do not respond to immunotherapy alone. A growing body of work has shown that e …
DNA vaccine for cancer immunotherapy.
Yang B, Jeang J, Yang A, Wu TC, Hung CF. Yang B, et al. Hum Vaccin Immunother. 2014;10(11):3153-64. doi: 10.4161/21645515.2014.980686. Hum Vaccin Immunother. 2014. PMID: 25625927 Free PMC article. Review.
DNA vaccination has emerged as an attractive immunotherapeutic approach against cancer due to its simplicity, stability, and safety. ...Despite all the practical advantages, DNA vaccines face challenges in inducing potent antigen specific cellular immune responses a …
DNA vaccination has emerged as an attractive immunotherapeutic approach against cancer due to its simplicity, stability, and safety. …
Roles of cancer/testis antigens (CTAs) in breast cancer.
Li Y, Li J, Wang Y, Zhang Y, Chu J, Sun C, Fu Z, Huang Y, Zhang H, Yuan H, Yin Y. Li Y, et al. Cancer Lett. 2017 Jul 28;399:64-73. doi: 10.1016/j.canlet.2017.02.031. Epub 2017 Mar 6. Cancer Lett. 2017. PMID: 28274891
In this regard, cancer testis antigens (CTAs) have emerged as a potential clinical biomarker targeting immunotherapy for various malignancies due to the nature of its characteristics. ...Moreover, TAAs could be therapeutic targets for cancer
In this regard, cancer testis antigens (CTAs) have emerged as a potential clinical biomarker targeting immunotherapy
Cancer-testis antigens: Unique cancer stem cell biomarkers and targets for cancer therapy.
Gordeeva O. Gordeeva O. Semin Cancer Biol. 2018 Dec;53:75-89. doi: 10.1016/j.semcancer.2018.08.006. Epub 2018 Aug 29. Semin Cancer Biol. 2018. PMID: 30171980 Review.
Cancer-testis antigens (CTAs) are considered as unique and promising cancer biomarkers and targets for cancer therapy. CTAs are multifunctional protein group with specific expression patterns in normal embryonic and adult cells and various types
Cancer-testis antigens (CTAs) are considered as unique and promising cancer biomarkers and targets for cancer
The role of the cancer testis antigen PRAME in tumorigenesis and immunotherapy in human cancer.
Xu Y, Zou R, Wang J, Wang ZW, Zhu X. Xu Y, et al. Cell Prolif. 2020 Mar;53(3):e12770. doi: 10.1111/cpr.12770. Epub 2020 Feb 5. Cell Prolif. 2020. PMID: 32022332 Free PMC article. Review.
Preferentially expressed antigen in melanoma (PRAME), which belongs to the cancer/testis antigen (CTA) gene family, plays a pivotal role in multiple cellular processes and immunotherapy response in human cancers. ...Therefore, the modulation of …
Preferentially expressed antigen in melanoma (PRAME), which belongs to the cancer/testis antigen (CTA) gene fami …
MAGE-A antigens as targets for cancer immunotherapy.
Schooten E, Di Maggio A, van Bergen En Henegouwen PMP, Kijanka MM. Schooten E, et al. Cancer Treat Rev. 2018 Jun;67:54-62. doi: 10.1016/j.ctrv.2018.04.009. Epub 2018 Apr 26. Cancer Treat Rev. 2018. PMID: 29763778 Review.
The intracellular MAGE proteins belong to a sub-class of Cancer Testis (CT) antigens which are expressed in germline cells and a wide variety of tumors of different histological origin. ...We present and analyze study outcomes and discuss possible future dire …
The intracellular MAGE proteins belong to a sub-class of Cancer Testis (CT) antigens which are expressed in germline ce …
Comprehensive analyses of tumor immunity: implications for cancer immunotherapy.
Li B, Severson E, Pignon JC, Zhao H, Li T, Novak J, Jiang P, Shen H, Aster JC, Rodig S, Signoretti S, Liu JS, Liu XS. Li B, et al. Genome Biol. 2016 Aug 22;17(1):174. doi: 10.1186/s13059-016-1028-7. Genome Biol. 2016. PMID: 27549193 Free PMC article.
RESULTS: We analyze tumor-infiltrating immune cells in over 10,000 RNA-seq samples across 23 cancer types from The Cancer Genome Atlas (TCGA). ...Analysis of cancer/testis antigen expression and CD8 T-cell abundance suggests that MAGEA3 is a pot …
RESULTS: We analyze tumor-infiltrating immune cells in over 10,000 RNA-seq samples across 23 cancer types from The Cancer Geno …
894 results
Jump to page
Feedback